## antibodies -online.com







## **IL29 Protein**



$\sim$			
	N/F	ا/\r14	iew/

Overview		
Quantity:	1 mg	
Target:	IL29	
Origin:	Human	
Source:	Escherichia coli (E. coli)	
Biological Activity:	Active	
Product Details		
Sequence:	GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES	
Characteristics:	Fully biologically active when compared to standard. The ED50 is determined in an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is typically 1-5 ng/ml,corresponding to a specific activity of > 2.0×105 units/mg.	
Purity:	> 97 % by SDS-PAGE and HPLC analyses.	
Endotoxin Level:	Level Less than 1EU/μg of rHuIFN-lambda1 as determined by LAL method	
Target Details		
Target:	IL29	
Alternative Name:	Interferon-Lambda1 (IFN-Lambda1) (IL29 Products)	
Background:	IL-28A, IL-28B, and IL-29, also named interferon-lambda2 (IFN-lambda2), IFN-lambda3, and IFN-lambda1, respectively, are newly identified class II cytokine receptor ligands that are distantly	

related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 Rbeta) and a novel IL-28 receptor alpha (IL-28 Ralpha, also known as IFN-lambdaR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. Synonym: Interferon-lambda1 (IFN-lambda1), Human. Formulation: Lyophilized from a 0.2µm filtered concentrated solution in 20mM PB, pH 7.4, 130mM NaCl.

Molecular Weight:

Approximately 19.8 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.

## **Application Details**

Restrictions:

For Research Use only

## Handling

Format:	Lyophilized
Reconstitution:	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
	bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a
	concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots
	and stored at < -20 °C. Further dilutions should be made in appropriate buffered solutions.
Storage:	4 °C